Mereo BioPharma Group plc (NASDAQ: MREO) Faces Class Action Lawsuit Alleging Misled Investors

jueves, 5 de febrero de 2026, 11:34 am ET1 min de lectura
MREO--

Rosen Law Firm is investigating allegations that Mereo BioPharma Group plc misled investors about its business operations, specifically regarding the Phase 3 ORBIT and COSMIC programs. The lawsuit claims that the true details of the programs' performance, which failed to meet primary endpoints, were concealed from investors. Shareholders who purchased Mereo ADS between June 5, 2023, and December 26, 2025, may be eligible to participate in the class action.

Mereo BioPharma Group plc (NASDAQ: MREO) Faces Class Action Lawsuit Alleging Misled Investors

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios